Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) was down 24% during mid-day trading on Wednesday . The stock traded as low as C$0.37 and last traded at C$0.38. Approximately 120,484 shares changed hands during trading, an increase of 1,333% from the average daily volume of 8,405 shares. The stock had previously closed at C$0.50.
Aptose Biosciences Stock Performance
The company has a debt-to-equity ratio of 670.80, a quick ratio of 5.41 and a current ratio of 0.80. The company has a market capitalization of C$6.70 million, a price-to-earnings ratio of -0.09 and a beta of 1.36. The company’s fifty day simple moving average is C$0.52 and its two-hundred day simple moving average is C$0.86.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- Golden Cross Stocks: Pattern, Examples and Charts
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Williams-Sonoma Stock: Buy It and Never Let It Go
- NYSE Stocks Give Investors a Variety of Quality Options
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
